Trial of Verapamil in Chronic Rhinosinusitis

• Status: Terminated
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benjamin Bleier; Massachusetts Eye and Ear Infirmary
• Treatments: Verapamil

Criteria

Inclusion Criteria:

1. Patients presenting to the Massachusetts Eye and Ear Sinus Center

2. Age 18-80 yrs old

3. Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria

Exclusion Criteria:

1. Patients with the following comorbidities:

• GI Hypomotility

• Heart Failure

• Liver Failure

• Kidney Disease

• Muscular Dystrophy

• Pregnant or Nursing Females

• Steroid Dependency

2. Patients taking the following medications:

• Aspirin

• Beta-blockers

• Cimetidine(Tagamet)

• Clarithromycin(Biaxin)

• Cyclosporin

• Digoxin

• Disopyramide(Norpace)

• Diuretics

• Erythromycin

• Flecainide

• HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir)

• Quinidine

• Lithium

• Pioglitazone

• Rifampin

• St Johns Wort

3. Patients with cardiac or conduction abnormality picked up by screening EKG